MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

Search

Bayer AG

Закрыт

СекторФинансы

21.29 -0.37

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

20.405

Макс.

21.835

Ключевые показатели

By Trading Economics

Доход

3.9B

-328M

Продажи

1.8B

12B

P/E

Средняя по отрасли

30.9

22.015

Прибыль на акцию

1.05

Дивидендная доходность

0.49

Рентабельность продаж

-2.796

Сотрудники

90,587

EBITDA

615M

1.7B

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+25.54% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.49%

3.90%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

422M

22B

Предыдущая цена открытия

21.66

Предыдущая цена закрытия

21.29

Новостные настроения

By Acuity

26%

74%

87 / 542 Рейтинг в Finance

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Bayer AG График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 мар. 2025 г., 09:37 UTC

Главные движущие силы рынка

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 мар. 2025 г., 11:21 UTC

Отчет

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5 мар. 2025 г., 08:45 UTC

Отчет

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5 мар. 2025 г., 07:26 UTC

Отчет

Bayer Warns of Lower Earnings as Work Continues on Turnaround

2 апр. 2025 г., 09:27 UTC

Популярные акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 мар. 2025 г., 08:38 UTC

Обсуждения рынка

Bayer's Partial Recovery Is in Sight -- Market Talk

5 мар. 2025 г., 13:39 UTC

Обсуждения рынка
Отчет

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5 мар. 2025 г., 13:26 UTC

Обсуждения рынка

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5 мар. 2025 г., 08:30 UTC

Обсуждения рынка
Отчет

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5 мар. 2025 г., 06:41 UTC

Отчет

Bayer Launches Plan to Boost Profitability at Crop Science

5 мар. 2025 г., 06:40 UTC

Отчет

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5 мар. 2025 г., 06:39 UTC

Отчет

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5 мар. 2025 г., 06:39 UTC

Отчет

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5 мар. 2025 г., 06:36 UTC

Отчет

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5 мар. 2025 г., 06:35 UTC

Отчет

Bayer Guidance is on a Currency Adjusted Basis

5 мар. 2025 г., 06:34 UTC

Отчет

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5 мар. 2025 г., 06:34 UTC

Отчет

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5 мар. 2025 г., 06:33 UTC

Отчет

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5 мар. 2025 г., 06:33 UTC

Отчет

Bayer Sees 2025 Sales EUR45B-EUR47B

5 мар. 2025 г., 06:32 UTC

Отчет

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5 мар. 2025 г., 06:31 UTC

Отчет

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5 мар. 2025 г., 06:31 UTC

Отчет

Bayer 4Q Net Loss EUR335M

5 мар. 2025 г., 06:31 UTC

Отчет

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5 мар. 2025 г., 06:31 UTC

Отчет

Bayer 4Q Ebitda Before Special Items EUR2.35B

5 мар. 2025 г., 06:31 UTC

Отчет

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5 мар. 2025 г., 06:31 UTC

Отчет

Bayer 4Q Sales EUR11.73B

13 янв. 2025 г., 21:05 UTC

Главные новости

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9 янв. 2025 г., 15:06 UTC

Приобретения, слияния, поглощения

Bayer Didn't Disclose Financial Details

9 янв. 2025 г., 15:05 UTC

Приобретения, слияния, поглощения

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9 янв. 2025 г., 15:05 UTC

Приобретения, слияния, поглощения

Bayer: Camelina Is Novel Intermediate Oilseed Crop

Сравнение c конкурентами

Изменение цены

Bayer AG Прогноз

Целевая цена

By TipRanks

25.54% рост

Прогноз на 12 месяцев

Средняя 26.89 EUR  25.54%

Максимум 33 EUR

Минимум 22 EUR

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Bayer AG  на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

10 ratings

1

Покупка

9

Удержание

0

Продажа

Техническая оценка

By Trading Central

N/A / 22.575Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

87 / 542Рейтинг в Финансы

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.